Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleAuthors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".AuthorsLenze, Eric J.; Reiersen, Angela M.; Facente, Shelley N.SubjectsANTIDEPRESSANTS; COVID-19; FLUVOXAMINE; ANTI-inflammatory agents; ANTIVIRAL agents; IMMUNOLOGICAL adjuvants; MENTAL depression; EARLY medical intervention; PHARMACODYNAMICSPublicationDrugs, 2022, Vol 82, Issue 3, p353ISSN0012-6667Publication typeLetter to the EditorDOI10.1007/s40265-022-01681-8